112 related articles for article (PubMed ID: 3137682)
1. Investigations on the role of arachidonic acid metabolism pathways in the antithrombotic activity of nafazatrom and molsidomine.
Massad L; Plotkine M; Boulu RG
Thromb Res; 1988 Jun; 50(5):617-25. PubMed ID: 3137682
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom.
Marnett LJ; Siedlik PH; Ochs RC; Pagels WR; Das M; Honn KV; Warnock RH; Tainer BE; Eling TE
Mol Pharmacol; 1984 Sep; 26(2):328-35. PubMed ID: 6434940
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro effects of nafazatrom (Bay g 6575), an antithrombotic compound, on arachidonic acid metabolism in platelets and vascular tissue.
Fischer S; Struppler M; Weber PC
Biochem Pharmacol; 1983 Jul; 32(14):2231-6. PubMed ID: 6688182
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of arterial thrombosis and platelet function by nafazatrom.
Buchanan MR; Blajchman M; Hirsh J
Thromb Res; 1982 Oct; 28(2):157-70. PubMed ID: 6758186
[TBL] [Abstract][Full Text] [Related]
5. Nafazatrom (BAY g 6575), a potent stimulator of prostacyclin release from cardiac and renal vessel wall.
Klitzke AK
Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):220-8. PubMed ID: 6391401
[TBL] [Abstract][Full Text] [Related]
6. Nafazatrom (Bay g-6575), an antithrombotic and antimetastatic agent, inhibits 15-hydroxyprostaglandin dehydrogenase.
Wong PY; Chao PH; McGiff JC
J Pharmacol Exp Ther; 1982 Dec; 223(3):757-60. PubMed ID: 6754908
[TBL] [Abstract][Full Text] [Related]
7. Antiaggregatory efficacy and its time-course after application of acetylsalicylic acid, prostacyclin and nafazatrom in vivo.
Herrmann KS
Arch Int Pharmacodyn Ther; 1984 Nov; 272(1):150-8. PubMed ID: 6393886
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of leukotriene B4 formation in human neutrophils after oral nafazatrom (Bay g 6575).
Strasser T; Fischer S; Weber PC
Biochem Pharmacol; 1985 Jun; 34(11):1891-4. PubMed ID: 2988560
[TBL] [Abstract][Full Text] [Related]
9. Platelet aggregation in arterioles of the hamster cheek pouch and in heart transplants: its tissue-dependent influencibility by acetylsalicylic acid and nafazatrom.
Herrmann KS; Seuter F
Haemostasis; 1984; 14(3):281-7. PubMed ID: 6381254
[TBL] [Abstract][Full Text] [Related]
10. Nafazatrom (Bay g 6575) blunts canine hypoxic pulmonary vasoconstriction: evidence for a prostaglandin-mediated mechanism.
Ensley RD; Rubin LJ
Prostaglandins Leukot Med; 1985 Apr; 18(1):95-104. PubMed ID: 3923499
[TBL] [Abstract][Full Text] [Related]
11. Effects of combinations of a prostacyclin analogue (Cicaprost) with different antithrombotic agents in a rat microcirculatory thrombosis model.
Giedrojc J; Breddin HK
Int J Microcirc Clin Exp; 1992 Aug; 11(3):277-86. PubMed ID: 1324230
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of nafazatrom-induced inhibition of rat uterus contractions in vitro.
Cantabrana B; Velasco G; Andrès-Trelles F; Hidalgo A
Arch Int Pharmacodyn Ther; 1989; 301():285-98. PubMed ID: 2560365
[TBL] [Abstract][Full Text] [Related]
13. The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetized greyhounds.
Coker SJ; Parratt JR
J Mol Cell Cardiol; 1984 Jan; 16(1):43-52. PubMed ID: 6366241
[TBL] [Abstract][Full Text] [Related]
14. Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs.
Weichert W; Pauliks V; Breddin HK
Haemostasis; 1983; 13(1):61-71. PubMed ID: 6132858
[TBL] [Abstract][Full Text] [Related]
15. Nafazatrom, an arachidonate metabolism inhibitor, decreases prolactin and GH release.
Judd AM; Login IS; Ehreth JT; MacLeod RM
Eur J Pharmacol; 1986 Sep; 128(3):151-6. PubMed ID: 3792440
[TBL] [Abstract][Full Text] [Related]
16. Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function.
Bednar M; Smith B; Pinto A; Mullane KM
Circ Res; 1985 Jul; 57(1):131-41. PubMed ID: 2988818
[TBL] [Abstract][Full Text] [Related]
17. Drug effects on output of prostacyclin from isolated lungs.
Bakhle YS; Pankhania JJ
Biochem Pharmacol; 1987 Oct; 36(20):3540-3. PubMed ID: 3118880
[No Abstract] [Full Text] [Related]
18. Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone. Requirement for peroxidative metabolism.
Reed GA; Griffin IO; Eling TE
Mol Pharmacol; 1985 Jan; 27(1):109-14. PubMed ID: 3917545
[TBL] [Abstract][Full Text] [Related]
19. Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom.
Deckmyn H; Van Houtte E; Verstraete M; Vermylen J
Biochem Pharmacol; 1983 Sep; 32(18):2757-62. PubMed ID: 6578796
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of nafazatrom.
Seuter F; Busse WD
Thromb Res Suppl; 1983; 4():75-80. PubMed ID: 6415860
[No Abstract] [Full Text] [Related]
[Next] [New Search]
